EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Serum antineuronal antibodies in patients with post-COVID-19 condition − association to intensive care

Tatiana Posharina, Mikko Varonen, Hanna Jarva, Mari Kanerva, Helena Liira, Sini M Laakso

Brain, Behavior, and Immunity · 2025

DOI: 10.1016/j.bbi.2025.05.026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, Behavior, and Immunity, 2025. Verfasst von Tatiana Posharina und 5 weiteren Autor:innen. Beteiligte Einrichtung: Outpatient Clinic for Long-Term Effects of COVID-19, University of Helsinki and Helsinki University Central Hospital, Paciuksenkatu 21, 00270 Helsink…. Hauptthemen laut MEDLINE: COVID-19, Autoantibodies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-COVID-19 condition (PCC), characterized by persistent symptoms following SARS-CoV-2 infection, is a global health challenge. Neurological symptoms are common in PCC, and immune-mediated mechanisms have been proposed as potential contributors. We set out to systematically explore serum antineuronal antibodies in patients with PCC and clinical factors associated with seropositivity. Our prospective, single-center cohort study included adult patients with a confirmed SARS-CoV-2 infection at least three months prior and a diagnosis of PCC. Serum and cerebrospinal fluid (CSF) samples were analyzed for the presence of antineuronal antibodies. A control group with confirmed SARS-CoV-2 infection but without PCC symptoms was included, age-, sex- and time from acute infection to sampling -matched to seropositive cases of PCC. Among 314 consecutive patients with PCC, 38 (12.1 %) tested positive for serum antineuronal antibodies. CSF analysis was performed for a subset; however, no intrathecal autoantibodies were detected. The most prevalent serum autoantibodies targeted CASPR-2 (n = 7, 18.9 %), neurofascin-186 (n = 5, 13.2 %), and glycine receptor (n = 4, 10.8 %). Multinomial logistic regression identified intensive care unit (ICU) admission during acute COVID-19 as the only significant predictor of autoantibody positivity (OR 3.4; 95 % CI: 1.0-10.4). Of the 35 control subjects, two (5.7 %) tested seropositive: one with low titer myelin oligodendrocyte glycoprotein antibodies and another with borderline myelin antibody levels. None of the patients met criteria for autoimmune encephalitis, and neurological assessments and brain magnetic resonance imaging were unremarkable. Neuropsychological testing showed a trend toward impairments in attention and executive functions among seropositive individuals. Thus, there was no significant difference in the prevalence of serum antineuronal antibodies in PCC compared to post-infection controls, and the association between seropositivity and ICU admission suggested systemic immune activation rather than a specific autoantibody-mediated mechanism. It remains unclear whether observed neuropsychological deficits are attributable to autoantibodies or the effects of critical illness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19AutoantibodiesHumansFemaleMaleMiddle AgedProspective StudiesAgedSARS-CoV-2Critical CareAdultNerve Tissue ProteinsNerve Growth FactorsMembrane Proteins

Stichwörter der Autor:innen

Antineuronal antibodiesCOVID-19Long covidPost Covid-19 condition

Substanzen

AutoantibodiesCNTNAP2 protein, humanNerve Tissue ProteinsNerve Growth FactorsMembrane Proteins

Autor:innen und Institutionen

  • Outpatient Clinic for Long-Term Effects of COVID-19, University of Helsinki and Helsinki University Central Hospital, Paciuksenkatu 21, 00270 Helsinki, Finland. Electronic address: tatiana.posharina@hus.fi.
  • Outpatient Clinic for Long-Term Effects of COVID-19, University of Helsinki and Helsinki University Central Hospital, Paciuksenkatu 21, 00270 Helsinki, Finland; Rehabilitation Outpatient Clinic for Persistent Symptoms,…
  • HUS Diagnostic center, University of Helsinki and Helsinki University Central Hospital, Finland.
  • Outpatient Clinic for Long-Term Effects of COVID-19, University of Helsinki and Helsinki University Central Hospital, Paciuksenkatu 21, 00270 Helsinki, Finland; Turku University Hospital and University of Turku, Turku,…
  • Translational Immunology Research Program, University of Helsinki and Brain Center, Helsinki University Hospital, Helsinki, Finland.

Zitieren

APA

Posharina, T., Varonen, M., Jarva, H., Kanerva, M., Liira, H., & Laakso, S. M. (2025). Serum antineuronal antibodies in patients with post-COVID-19 condition − association to intensive care. Brain, Behavior, and Immunity. https://doi.org/10.1016/j.bbi.2025.05.026

Vancouver

Posharina T, Varonen M, Jarva H, Kanerva M, Liira H, Laakso SM. Serum antineuronal antibodies in patients with post-COVID-19 condition − association to intensive care. Brain, Behavior, and Immunity. 2025. doi:10.1016/j.bbi.2025.05.026

BibTeX
@article{Posharina2025,
  author = {Posharina, Tatiana and Varonen, Mikko and Jarva, Hanna and Kanerva, Mari and Liira, Helena and Laakso, Sini M},
  title = {Serum antineuronal antibodies in patients with post-COVID-19 condition − association to intensive care},
  journal = {Brain, Behavior, and Immunity},
  year = {2025},
  doi = {10.1016/j.bbi.2025.05.026}
}
Kostenlos starten →